Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-threonine is the unnatural enantiomer of the amino acid threonine. Unlike L-threonine—which is proteinogenic and essential in humans—D-threonine is not incorporated into proteins but serves as a chiral building block in chemical synthesis and pharmaceutical manufacturing. It belongs to the class of organic compounds known as d-alpha-amino acids and has applications as a synthetic intermediate for chiral antibiotics and other chiral compounds. In biological systems such as yeast (Saccharomyces cerevisiae), it can act as a metabolite. Experimentally, it has been shown to inhibit growth and cell wall synthesis in certain bacteria like Mycobacterium smegmatis[1][3][4][5][6]. There are no approved medical indications or clinical uses for D-threonine in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-threonine.